Hollow Brook Wealth Management LLC Trims Position in Amgen Inc. $AMGN

Hollow Brook Wealth Management LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 54.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,312 shares of the medical research company’s stock after selling 1,548 shares during the quarter. Hollow Brook Wealth Management LLC’s holdings in Amgen were worth $429,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in AMGN. Norges Bank purchased a new position in shares of Amgen in the 4th quarter worth $2,164,162,000. Capital World Investors raised its position in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after buying an additional 4,302,237 shares during the period. State Street Corp raised its position in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the period. Geode Capital Management LLC raised its position in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after buying an additional 1,035,779 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after buying an additional 961,975 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 1.3%

Shares of NASDAQ AMGN opened at $350.53 on Tuesday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The company has a market cap of $189.18 billion, a P/E ratio of 24.39, a P/E/G ratio of 3.56 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a fifty day moving average price of $341.03 and a 200 day moving average price of $345.86.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the prior year, the firm earned $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Truist Financial increased their target price on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a research report on Friday, May 1st. Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. UBS Group increased their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Canaccord Genuity Group initiated coverage on Amgen in a research report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $354.42.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.